INMED PHARMACEUTICALS INC. Provision for Other Credit Losses
INMED PHARMACEUTICALS INC. (INM) reported Provision for Other Credit Losses of $2.42 thousand for the 12-month period ending 2025-06-30, per its S-4 filed 2026-07-02.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ProvisionForOtherCreditLosses · last filed 2026-07-02
| Period end | Provision for Other Credit Losses 12 month |
|---|---|
| 2025-06-30 | $2.42K S-4 · filed 2026-07-02 |
| 2024-06-30 | $0.00 S-4 · filed 2026-07-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |